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Abstract: Gliomas are the most common primary human brain tumors. They comprise a 
heterogeneous group of benign and malignant neoplasms that are histologically classified 
according to the World Health Organization (WHO) classification of tumors of the 
nervous system. Over the past 20 years the cytogenetic and molecular genetic alterations 
associated with glioma formation and progression have been intensely studied and 
genetic profiles as additional aids to the definition of brain tumors have been 
incorporated in the WHO classification. In fact, first steps have been undertaken in 
supplementing classical histopathological diagnosis by the use of molecular tests, such as 
MGMT promoter hypermethylation in glioblastomas or detection of losses of 
chromosome arms 1p and 19q in oligodendroglial tumors. The tremendous progress that 
has been made in the use of array-based profiling techniques will likely contribute to a 
further molecular refinement of glioma classification and lead to the identification of 
glioma core pathways that can be specifically targeted by more individualized glioma 
therapies.  
Keywords:  Glioblastoma, oligodendroglioma, ependymoma, molecular diagnostics, 
genetics, MGMT, 1p, 19q, biomarker, profiling. 
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1. Introduction 
Primary tumors of the central nervous system (CNS) account for approximately 2-3% of all 
cancers. In Western countries, the annual incidence is approximately 15 patients per 100,000 
population and the prevalence has been estimated to approximately 69 patients per 100,000 population 
[1]. In children, CNS tumors are the second most common form of cancer after leukemia. Primary 
CNS tumors comprise a heterogeneous group of benign and malignant neoplasms, the most common 
of which are tumors of glial cells, collectively referred to as gliomas [1]. Gliomas are histologically 
classified according to the World Health Organization (WHO) classification of tumors of the nervous 
system [2], which combines tumor typing with the assignment of a defined malignancy grade (Table 
1). Four histological malignancy grades have been defined that reach from benign tumors of WHO 
grade I to highly malignant tumors of WHO grade IV. Pilocytic astrocytoma, the most common glioma 
in childhood, is the prototype of a WHO grade I lesion. On the other end of the spectrum, WHO grade 
IV is assigned to glioblastoma, the most common and most malignant type of glioma, which 
preferentially manifests in adults with a peak incidence between 50 and 60 years (Table 1). 
The histological classification and grading to date still represents the most reliable and meaningful 
indicator for the biological and clinical behavior of gliomas as well as patient outcome. Patients with 
WHO grade I tumors can usually be cured by surgical resection. WHO grade II tumors -though still 
exhibiting a rather slow growth- nearly invariably recur after resection and bear the inevitable 
tendency to progress to anaplastic gliomas of WHO grade III or secondary glioblastomas of WHO 
grade IV. Thus, median survival of patients with WHO grade II gliomas is in the range of only 5 – 8 
years after diagnosis. Anaplastic gliomas (WHO grade III) are rapidly growing malignant tumors that, 
in addition to surgery, require aggressive adjuvant treatment with radio- and/or chemotherapy.  Median 
survival time is just 2-3 years after diagnosis, except for the subgroup of patients with anaplastic 
oligodendroglial tumors, who often do better, in particular when their tumors carry a prognostically 
favorable combined deletion of chromosomal arms 1p and 19q, as outlined below [3, 4]. Glioblastoma 
patients exhibit a rapid disease progression despite multimodal aggressive treatment and median 
survival time -with few exceptions- is in the range of just one year after initial diagnosis.        
Research efforts of the past decades identified a plethora of cytogenetic and molecular genetic 
alterations in gliomas that may be exploited to facilitate glioma classification, especially in cases that 
exhibit inconclusive or borderline histological features. In this review, we will provide a 
comprehensive overview of the cytogenetic and molecular alterations that are associated with the 
individual glioma entities and describe their role in regard to glioma initiation and progression. Special 
emphasis will be put on the introduction of those molecular biomarkers that have been established in 
glioma diagnostics, namely MGMT promoter hypermethylation in glioblastomas and deletion of 
chromosome arms 1p and 19q in patients with oligodendroglial tumors. Finally, we will highlight the 
tremendous impact that high-troughput profiling techniques, such as gene expression profiling, array-
CGH, methylation profiling and large-scale sequencing, have on the genome-wide identification of 
novel tumor suppressor and proto-oncogenes. Integrative analysis over the different platforms will not 
only expand our knowledge of the molecular basis of gliomas but also pave the way to a molecularly 
refined glioma classification and facilitate the detection of “genes in context”, i.e. pathways of 
gliomagenesis that can be specifically targeted with individualized therapies.  Int. J. Mol. Sci. 2009, 10  
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Table 1. Classification and grading of the main glioma subtypes according to the WHO 
classification of tumors of the central nervous system [2]. 
Tumor type    WHO grade 
Diffusely infiltrating astrocytic gliomas 
Diffuse astrocytoma 
Anaplastic astrocytoma 
Glioblastoma  
Giant cell glioblastoma 
Gliosarcoma  
II 
III 
IV 
IV 
IV 
Astrocytic gliomas with more circumscribed growth     
Pilocytic astrocytoma 
Pilomyxoid astrocytoma 
Pleomorphic xanthoastrocytoma 
Subependymal giant cell astrocytoma 
I 
II 
II 
I 
Oligodendrogliomas and mixed gliomas  
Oligodendroglioma 
Anaplastic oligodendroglioma 
Oligoastrocytoma 
Anaplastic oligoastrocytoma 
II 
III 
II 
III 
Gliomas with ependymal differentiation 
Subependymoma  
Myxopapillary ependymoma 
Ependymoma  
Anaplastic ependymoma  
I 
I 
II 
III 
 
2. Cytogenetic and molecular changes within individual glioma types 
 
2.1. Diffusely infiltrating astrocytic gliomas 
 
2.1.1. Diffuse astrocytoma (WHO grade II) 
 
The most common chromosomal abnormality in diffuse astrocytomas of WHO grade II is trisomy 7 
or at least a gain of 7q, which has been detected by comparative genomic hybridization in 50% of the 
cases [5, 6]. However, the relevant target genes on chromosome 7 have not yet been identified. Further Int. J. Mol. Sci. 2009, 10  
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chromosomal aberrations comprise losses on 22q, 19q, 13q, 10p, 6 and the sex chromosomes as well 
as gains on 5p, 9 and 19p [7].  
The most common molecular alterations are mutations of the TP53 tumor suppressor gene at 
17q13.1 in about 60% of cases as well as the just recently identified codon 132 mutations of the 
isocitrate dehydrogenase 1 (IDH1) gene in about 70% of diffuse astrocytomas [8-10] (Figure 1).  
 
Figure 1. Schematic representation of the molecular pathogenesis and progression of 
diffusely infiltrating astrocytic gliomas.  
 
 
 
Even higher frequencies of TP53 mutations of up to 80% are detectable in the gemistocytic 
astrocytoma variant [11]. TP53  mutations are regarded as one of the earliest events in the 
tumorigenesis of diffuse astrocytomas, since in most cases they are already present in the first biopsy 
and their frequency does not increase in recurrences. TP53 mutations in diffuse astrocytomas are 
commonly associated with loss of heterozygosity (LOH) at polymorphic loci on 17p resulting in 
complete loss of wild-type p53 in the tumor cells.  
In tumors without TP53 alterations, the p14
ARF gene at 9p21, the gene product of which regulates 
MDM2-mediated degradation of p53, is frequently methylated and transcriptionally downregulated Int. J. Mol. Sci. 2009, 10  
 
188
[12]. Other genes that are frequently epigenetically silenced in diffuse astrocytomas include the 
MGMT gene at 10q26 [12], the protocadherin-gamma subfamily A11 (PCDH-gamma-A11) gene at 
5q31 [13], and the EMP3 gene at 19q13 [14]. Interestingly, MGMT hypermethylation was found to be 
associated with TP53 mutation but is mutually exclusive to p14
ARF hypermethylation [12].  
Another common alteration in diffuse astrocytomas is overexpression of the platelet-derived growth 
factor receptor alpha (PDGFRA) and its ligand PDGFalpha [15]; PDGFRA amplification, however, is 
restricted to a small subset of high-grade gliomas, in particular glioblastomas [16] (Figure 1). 
 
2.1.2. Anaplastic astrocytoma (WHO grade III) 
 
Anaplastic astrocytomas show gains of chromosome 7 and TP53 mutations as well as IDH1 
mutations at a similar frequency as diffuse astrocytomas. In addition, these tumors bear frequent allelic 
losses on chromosomes 6, 9p, 11p, 19q and 22q. The CDKN2A, p14
ARF and CDKN2B tumor 
suppressor genes are important targets for genetic and or epigenetic inactivation, with inactivation of 
p14
ARF serving as an alternative means to impair the p53 pathway in cases without TP53 mutations [8]. 
The gene products of CDKN2A,  i.e. p16
INK4a, and CDKN2B, i.e. p15
INK4b, function as negative 
regulators of the cell cycle at the G1/S-phase transition by inhibiting the formation of complexes 
between D-type cyclins and the cyclin dependent kinases Cdk4 or Cdk6. The CDK4 gene at 12q13-q14 
is amplified and overexpressed in about 10% of anaplastic astrocytomas [17], preferentially in tumors 
without CDKN2A deletion or mutation [18, 19].  
In addition, about 25% of anaplastic astrocytomas carry mutations in the retinoblastoma gene (RB1) 
[18] (Figure 1). In contrast to glioblastomas, allelic losses on 10q and mutation of the PTEN tumor 
suppressor gene on 10q23 are rare in anaplastic astrocytomas (<10% of cases). However, when 
present, PTEN mutation indicates a poor prognosis [20]. 
 
2.1.3. Glioblastoma (WHO grade IV) 
 
Glioblastomas usually carry multiple chromosomal and genetic aberrations. In addition to the above 
listed aberrations found in diffuse and anaplastic astrocytomas, glioblastomas typically exhibit loss of 
genetic material from chromosome 10. Interestingly, molecular genetic analyses over the past years 
have shed light on two different genetic pathways in glioblastoma formation establishing the concept 
of primary and secondary glioblastomas [21] (Figure 1). Primary glioblastomas arise de novo without 
the clinical history of a lower grade precursor lesion. Primary glioblastomas exhibit frequent EGFR 
amplification, homozygous deletion of CDKN2A and p14
ARF, CDK4 amplification, MDM2 or MDM4 
amplification, RB1 mutation/homozygous deletion, monosomy 10 and PTEN mutation [21-25]. EGFR 
amplification is particularly frequent in primary glioblastomas with a small cell, highly anaplastic 
histological phenotype [26]. TP53 mutation is found in less than 30% of primary glioblastomas. In 
contrast, secondary glioblastomas arise from a lower-grade precursor lesion and carry TP53 and IDH1 
mutations in more than two thirds of the cases [10, 21]. Also, allelic losses on 19q and 13q, promoter 
hypermethylation of the RB1 gene, and overexpression of PDGFRA are more common in secondary 
glioblastomas [21, 22, 27]. Amplification of EGFR or MDM2, PTEN mutation as well as homozygous 
CDKN2A or p14
ARF deletions are all rare in secondary glioblastomas. Also epigenetic silencing of Int. J. Mol. Sci. 2009, 10  
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various genes has been described as overrepresented in either primary (NDRG2) or secondary (MGMT 
and EMP3) glioblastomas [21, 28, 29]. Taken together, these data clearly indicate that primary and 
secondary glioblastomas represent genetically different disease entities (Figure 1). Nevertheless, both 
entities share comparable histological features and an equally poor prognosis. The fact that the 
different molecular alterations converge on the same downstream cellular pathways, namely the p53, 
pRb1, PTEN/PI3K/AKT and mitogen-activated protein kinase pathways, and thereby lead to similar 
functional consequences, may explain this phenomenon [7, 30, 31]. 
 
Breakout box 1: MGMT hypermethylation as a predictive marker in glioblastomas. 
The  MGMT (O
6-methylguanine–DNA methyltransferase) gene on chromosome band 10q26 
encodes a DNA repair protein that removes alkyl groups from the O
6 position of guanine, an 
important site of DNA alkylation [32]. Chemotherapy-induced alkylation in this location triggers 
cytotoxicity and apoptosis. High levels of the MGMT repair protein thus may counteract the 
therapeutic effect of alkylating agents and thereby lead to treatment failure. Epigenetic silencing of 
MGMT by means of promoter hypermethylation is present in about 40% of primary glioblastomas 
and has been identified as the main mechanism reducing MGMT expression and thereby 
diminishing its DNA repair activity. Importantly, MGMT promoter methylation has been 
associated with response of glioblastomas to alkylating chemotherapy using nitrosourea 
compounds [33], temozolomide [34], or a combination of both [35]. Based on MGMT promoter 
methylation analysis in glioblastomas from patients treated in a large prospective clinical trial, 
patients whose tumors had a methylated MGMT promoter survived significantly longer as 
compared to patients whose tumors lacked MGMT promoter methylation when treated with 
combined radio-/ chemotherapy [34]. In glioblastoma patients treated with radiotherapy alone, 
MGMT promoter methylation did not significantly influence survival, thus indicating that the 
MGMT promoter status is a predictive factor for response to chemotherapy. As MGMT promoter 
methylation can be tested by methylation-specific polymerase chain reaction (MSP) analysis or 
other methods, MGMT testing is now increasingly being requested not only for patients in clinical 
trials but also in routine diagnostics. 
 
Giant cell glioblastomas carry TP53 mutations in up to 90% and PTEN mutations in 30-40% of 
cases, thus combining molecular features of both primary and secondary glioblastoma. EGFR 
amplification and homozygous deletions of CDKN2A and p14
ARF are usually absent [36, 37].  
The molecular genetics of gliosarcoma is fairly similar to that of primary glioblastoma, except for 
EGFR amplification, which seems to be less frequent [38]. Microdissection of the gliomatous and 
sarcomatous tumor components followed by CGH analysis revealed common genetic aberrations in 
both components, thus arguing for a monoclonal origin of both histological aspects of   
gliosarcomas [39].   
Rare glioblastomas may exhibit metaplastic histologic features with adenoid or squamous cell 
epithelial differentiation, bone or cartilage formation as well as xanthomatous or adipocytic changes. Int. J. Mol. Sci. 2009, 10  
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However, none of these alterations are as yet known to be reflected by distinct alterations on the 
molecular level [40-44]. 
 
2.2. Astrocytic gliomas with more circumscribed growth 
 
2.2.1. Pilocytic astrocytoma (WHO grade I) 
 
In pilocytic astrocytomas molecular and cytogenetic investigations have identified far less 
chromosomal and genetic alterations than in the diffusely infiltrating astrocytomas described above. 
Chromosomal comparative genomic hybridization (CGH) studies in 48 pilocytic astrocytomas 
revealed chromosomal imbalances only in a small subgroup of seven neoplasms [45] with gain of 
9q34.1-qter constituting the most common abnormality. Recurrent trisomies of chromosomes 5 and 
chromosome 7 have been reported in another study employing array-CGH on 53 pilocytic 
astrocytomas [46] (Figure 2).  
In patients with neurofibromatosis type 1 (NF1) pilocytic astrocytomas are the most common 
gliomas. In this setting, pilocytic astrocytomas are typically located in the optic nerve, often bilaterally, 
and carry allelic losses at the NF1 tumor suppressor gene locus at 17q11.2 [47]. Sporadic pilocytic 
astrocytomas, in contrast, rarely demonstrate allelic loss at the NF1 locus [47]. Furthermore, neither 
NF1 mutations nor loss of NF1 mRNA expression were found in sporadic pilocytic astrocytomas [48]. 
Losses on 17p and mutations in the TP53 tumor suppressor genes that are observed in diffuse 
astrocytomas are not a common feature in pilocytic astrocytomas [47, 49, 50]. In contrast, 
circumscribed duplication of the BRAF gene at 7q34 resulting in increased BRAF expression has been 
identified as a common aberration [46, 51-53]. BRAF duplication results in an in-frame fusion gene 
incorporating the kinase domain of the BRAF oncogene with constitutive BRAF kinase activity. A 
small subset of tumors alternatively carries activating BRAF mutations, thus implicating this gene as 
an important proto-oncogene in these tumors (Figure 2).  
 
Figure 2. Schematic representation of the molecular pathogenesis of pilocytic 
astrocytomas. 
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Recently, the pilomyxoid astrocytoma has been recognized as a histologically and clinically distinct 
variant of pilocytic astrocytoma with a less favorable prognosis [54]. Local recurrences as well as 
cerebrospinal spread occur more often in pilomyxoid tumors than in pilocytic astrocytomas. The WHO 
classification thus assigns these tumors to WHO grade II. Data on whether the histological and 
prognostic differences between pilocytic and pilomyxoid astrocytomas are also reflected by different 
genetic alterations at the molecular level are still scarce. A recent study employing gene expression 
profiling of NF1-associated and sporadic pilocytic and pilomyxoid astrocytomas identified aldehyde 
dehydrogenase 1 family member L1 (ALDH1L1) as an underexpressed candidate biomarker in more 
aggressive tumor subtypes [55]. 
 
2.2.2. Pleomorphic xanthoastrocytoma (WHO grade II) 
 
Loss on chromosome 9 is the most common genomic imbalance in pleomorphic xanthoastrocytoma 
(PXA), which is detectable by CGH analysis in 50% of cases. Other losses affect chromosomes 17 
(10%), 8, 18 and 22 (4% each). Chromosomal gains could be identified on chromosomes X (16%), 7, 
9q, 20 (8% each), 4, 5 and 19 (4% each) [56]. 
TP53 mutations are seen in a small fraction of tumors (<10% of cases), while 1p/19q losses as well 
as amplification of EGFR, CDK4 and MDM2 are absent [57, 58]. In contrast, homozygous deletion of 
the tumor suppressor genes CDKN2A,  p14
ARF and CDKN2B  on  9p21.3 is common in PXA [56].   
Interestingly, transcript levels of the TSC1 gene on 9q were found to be consistently low in PXA; 
however, the causative mechanism still remains unclear, as there was no evidence for TSC1 mutations 
or promoter methylation [56].   
 
2.2.3. Subependymal giant cell astrocytoma (WHO grade I) 
 
Biallelic inactivation of either the TSC1 or the TSC2 tumor suppressor gene is a hallmark for these 
tumors [59]. Since the corresponding gene products have an inhibitory function on the mTOR 
pathway, their mutational inactivation leads to aberrant activation of mTOR signaling, which in turn 
represents an interesting novel target for specific pharmacologic inhibition. A comparative genomic 
hybridization study on subependymal giant cell astrocytomas indicated that chromosomal imbalances 
are either rare or completely absent [40]. 
 
2.3. Oligodendrogliomas and mixed gliomas 
 
2.3.1. Oligodendroglioma (WHO grade II) 
 
Despite extensive research efforts, oligodendroglioma-specific immunohistochemical markers 
could not yet be identified [60-62]. However, the most characteristic genetic feature of 
oligodendroglial tumors is the combined loss of alleles on 1p and 19q, which may be detected in up to 
two thirds of the cases [63] (Figure 3).  
Two independent studies reported that an unbalanced t(1;19)(q10;p10) translocation, with the 
chromosomal breakpoints located close to the centromers of both chromosomes, serves as the Int. J. Mol. Sci. 2009, 10  
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cytogenetic mechanism responsible for the frequent co-deletions of both chromosome arms in 
oligodendrogliomas [64, 65]. The oligodendroglioma-associated tumor suppressor genes on 1p and 
19q, however, have not yet been identified. Recent studies indicate that more than one gene from 1p 
may be aberrant in oligodendrogliomas. The NOTCH2 gene maps closest to the breakpoint region on 
1p13-p11 and may function as a putative oligodendroglioma-associated tumor suppressor gene 
considering that intragenic homozygous deletions have been found in two tumors [66]. But also a 
number of other candidate tumor suppressor genes from different regions on 1p have been proposed, 
including TP73 (1p36.3), the calmodulin-binding transcription activator 1 gene (CAMTA1, 1p36), the 
DNA fragmentation factor subunit ß gene (DFFB, 1p36), SHREW1 (1p36.32), CITED4 (1p34.2), 
RAD54 (1p32), CDKN2C (1p32), and DIRAS3 (1p31) [67-73]. Candidate tumor suppressor genes on 
19q include the p190RhoGAP gene at 19q13.3 [74], the myelin-related epithelial membrane protein 
gene 3 (EMP3) at 19q13.3 [75], ZNF342, a zinc-finger transcription factor gene at 19q13 [76], and the 
maternally imprinted PEG3 gene at 19q13.4 [77].  
 
Figure 3. Schematic representation of the molecular pathogenesis and progression of 
oligodendrogliomas.  
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In addition to 1p/19q deletions, several other genetic and epigenetic alterations have been described 
in oligodendrogliomas (Figure 3). Less frequent cytogenetic alterations are gains on chromosomes 7 
and 19p as well as losses on chromosomes 4, 6, 9p, 10q, 11p, 14, 18q, and 22q [71, 78]. Some of these 
chromosomal imbalances have been suggested as being linked to poor outcome, including gain of 7p 
and 8q as well as losses on 9p and 18q [79]. Both oligodendrogliomas of WHO grade II as well as 
anaplastic oligodendrogliomas (WHO grade III) share the high frequency of IDH1 mutations (~70%) 
with astrocytic gliomas [9]. Allelic losses on 17p and TP53 gene mutations are rare in low-grade 
oligodendrogliomas as they are mutually exclusive to the frequent 1p/19q losses. Nevertheless 
functional inactivation of the p53 pathway in oligodendrogliomas may be achieved by means of 
epigenetic silencing of the p14
ARF gene, which thereby loses its ability to bind Mdm2 and to prevent 
the Mdm2-mediated degradation of p53 [80, 81].  
 
Breakout box 2: Combined deletion of chromosome arms 1p and 19q as a biomarker in 
(anaplastic) oligodendrogliomas.  
Anaplastic oligodendrogliomas with loss on 1p, or combined losses on 1p and 19q, usually 
respond favorably to chemotherapy, with about half of such tumors showing complete 
neuroradiological responses [91]. On the contrary, only 25% of the anaplastic oligodendrogliomas 
that lack these genetic changes respond to PCV. Furthermore, patients whose tumors have 1p or 
combined 1p and 19q losses show significantly longer survival (mean survival of > 10 years) as 
compared to patients whose tumors lack these genetic changes (mean survival of approximately 2 
years) [91, 92]. Initially reported by Cairncross and colleagues in 1998 [91], several retrospective 
studies have confirmed combined deletions of 1p and 19q as an independent marker of favorable 
response to radio- and chemotherapy as well as prolonged survival in patients with high-grade 
oligodendroglial tumors [87, 88, 92, 93]. Also, two prospective and randomized phase III trials 
involving 368 patients and 289 patients, respectively, confirmed the prognostic value of 1p/19q 
deletion in patients with anaplastic oligodendroglial tumors [3, 4]. Owing to the major prognostic 
significance of the 1p/19q status in patients with anaplastic gliomas treated with radio- and/or 
chemotherapy, ongoing prospective trials are no longer stratifying anaplastic glioma patients 
according to histological type but according to the 1p/19q deletion status. Thus, it is likely that 
molecular testing for 1p/19q deletion will become a routine adjunct to histology in the diagnostic 
assessment of anaplastic gliomas. The prognostic role of 1p/19q deletion in low-grade 
oligodendroglioma patients is less clear. Several recent studies independently reported that 1p 
deletion or 1p/19q co-deletion were also associated with a trend towards longer survival in low-
grade oligodendroglioma patients [89, 92-95], and that in patients treated with temozolomide 1p 
loss was associated with objective treatment response [96, 97]. Nevertheless, contrary findings also 
have been reported, which could not corroborate combined 1p/19q loss as a sensitive prognostic 
biomarker in patients with oligodendroglial tumors who did not receive radiotherapy or 
chemotherapy [98].   
 Int. J. Mol. Sci. 2009, 10  
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Other genes hypermethylated in oligodendrogliomas include the tumor suppressors CDKN2A, 
CDKN2B and RB1, as well as DAPK1 (death-associated protein kinase 1), ESR1 (estrogen receptor 1), 
THBS (thrombospondin 1) and TIMP3 (tissue inhibitor of metalloproteinase 3) [81-83]. Frequent 
promoter hypermethylation and reduced expression of the MGMT gene in oligodendrogliomas and 
consecutive impairment of MGMT-mediated DNA repair might in part contribute to the 
chemosensitivity of these neoplasms [84, 85]. 
Finally, oligodendrogliomas frequently demonstrate increased expression of growth factor 
receptors, such as EGFR and PDGFR [71, 86]. Platelet-derived growth factors A and B, as well as the 
corresponding receptors (PDGFR-alpha and PDGFR-beta) have been reported as constantly co-
expressed in oligodendrogliomas suggesting an auto- and/or paracrine growth stimulatory activity of 
this signaling pathway [86] (Figure 3). 
 
2.3.2. Anaplastic oligodendroglioma (WHO grade III) 
 
Malignant progression of oligodendroglial tumors is associated with the accumulation of multiple 
genetic abnormalities. Anaplastic oligodendrogliomas share the frequent loss of alleles on 1p and 19q 
with low-grade oligodendrogliomas, but additionally show frequent deletions on 9p and/or on 
chromosome 10 [87-89] (Figure 3). On 9p21, the tumor suppressor genes CDKN2A,  p14
ARF and 
CDKN2B are homozygously deleted in up to one third of anaplastic oligodendrogliomas [71, 78]. Such 
deletions are particularly common in anaplastic oligodendrogliomas without 1p and 19q losses, but 
may also be present in 1p/19q-deleted cases. PTEN mutations occur in only about half of the cases 
with 10q loss, suggesting that there might be another progression-related target gene in this region [88, 
89]. PTEN mutations and 10q deletions are more common in anaplastic oligodendrogliomas without 
1p and 19q losses. Rare anaplastic oligodendrogliomas carry activating mutations in the PIK3CA  
gene [90].  
Comparative genomic hybridization studies have uncovered that chromosomal imbalances on 
several other chromosomes occur at more than random frequency in anaplastic oligodendrogliomas, 
most notably losses on chromosomes 4, 6, 11, 13q, 18 and 22q as well as gains on chromosomes 7, 15 
and 20 [71, 78]. Gene amplifications affecting the EGFR, PDGFRA, CDK4, MDM4, MYC or MYCN 
are uncommon (generally <10%) [71, 78]. 
 
2.3.3. Oligoastrocytomas (WHO grade II or III) 
 
Oligoastrocytomas are histologically mixed glial neoplasms with oligodendroglial as well as 
astrocytic features. The oligodendroglial and astroglial tumor components may either be diffusely 
intermingled or separated into distinct tumor areas. Genetic alterations that would separate 
oligoastrocytomas from oligodendrogliomas on the one hand and diffuse astrocytomas on the other 
hand have not been detected. Roughly half of the oligoastrocytomas show allelic losses on 1p and 19q 
[71]. While in one study these aberrations were identical in oligodendroglial and astrocytic tumor 
parts, indicating a monoclonal origin of  oligoastrocytomas, other authors reported genetically distinct 
astrocytic and oligodendroglial components in a subset of oligoastrocytomas [99, 100]. About 30% of 
oligoastrocytomas carry genetic aberrations typical for diffuse astrocytomas, i.e. TP53 mutation and Int. J. Mol. Sci. 2009, 10  
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loss of heterozygosity on 17p [71]. Those oligoastrocytomas with TP53 mutation and 17p loss do not 
have LOH on 1p and 19q, and vice versa. Taken together, these data indicate that oligoastrocytomas 
are genetically heterogeneous with one subset being genetically related to oligodendrogliomas and 
another subset corresponding genetically to diffuse astrocytomas (Figure 4). 
 
Figure 4. Schematic representation of the molecular pathogenesis and progression of 
oligoastrocytomas. 
 
 
Oligoastrocytomas that are histologically highly anaplastic and contain areas of necrosis are 
referred to as “glioblastomas with oligodendroglial component, WHO grade IV”. While rare in classic 
glioblastomas (less than 10% of the cases), 1p/19q deletions may be more common in glioblastomas 
with an oligodendroglial component, which in part may account for the better survival associated with 
this particular glioblastoma subgroup [101].   
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2.4. Gliomas with ependymal differentiation 
 
2.4.1. Ependymoma (WHO grade II) 
 
The most common cytogenetic aberrations in ependymomas are losses of chromosomes 6q, 10, 13, 
14, and 22q, as well as gains of chromosomes 1q, 7, 9, 12q, 15q, and 18. Recent studies using CGH 
analysis reported on distinct patterns of chromosomal aberrations being linked to certain clinical and 
pathological features of ependymomas, such as patient age, tumor location, and histological subtype or 
WHO grade [102-106]. Losses on 22q and gains of chromosome 4 were more common in adult tumors 
[105]. Gains on 1q correlated with the presence of structural chromosomal aberrations, pediatric age, 
high-grade histology and aggressive clinical behavior [102, 103, 105]. While spinal intramedullary 
ependymomas preferentially demonstrated losses of chromosomes 22q and 14q as well as gains on 
chromosomes 7q, 9p and 16, intracranial ependymomas frequently carried gains of 1q and losses on 6q 
(Figure 5). The distinct genetic profiles associated with tumor location were also reflected in 
regionally different mRNA expression signatures. Supratentorial ependymomas, for example, 
expressed elevated levels of members of the EPHB-EPHRIN and NOTCH families, whereas spinal 
ependymomas showed up-regulated expression of multiple HOX gene family members [106]. 
 
Figure 5. Schematic representation of the molecular pathogenesis and progression of 
ependymal gliomas.   
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Molecular genetic studies on selected candidate genes revealed frequent NF2 gene mutations in 
intramedullary spinal ependymomas, while deletions of the CDKN2A gene were frequent in 
intracranial supratentorial ependymomas but rare in ependymomas from other locations [106] (Figure 
5). Mutations in the TP53, PTEN and INI1 tumor suppressor genes are not a common feature in 
ependymomas [107-109]. The tumors suppressor genes RASSF1, CDKN2A, CDKN2B, p14
ARF and 
TP73, as well as other genes potentially involved in the tumorigenesis of ependymomas, such as 
CASP1, MGMT, TIMP3 and THBS1 are epigenetically silenced by aberrant promoter methylation in 
subsets of ependymomas [110, 111]. As in other gliomas, growth factor receptors, such as EGFR and 
the related ERBB2 and ERBB4 receptors, are commonly upregulated in ependymal tumors; 
amplifications of the respective genes, however, do not usually occur in low-grade ependymomas 
[105, 112]. 
 
2.4.2. Anaplastic ependymoma (WHO grade III) 
 
The molecular changes observed in anaplastic ependymomas are fairly similar to those observed in 
their low-grade counterparts. Though to a certain extent malignant progression in ependymomas may 
occur, only few molecular changes have been pinpointed that are more or less exclusively associated 
with a high-grade ependymoma phenotype. In an analysis of 23 anaplastic ependymomas, loss of 
chromosome arm 10q appeared overrepresented [107]. Also, gain of 1q, with DUSP12 on 1q23 as a 
potential target gene [105], as well as losses of 9 and 13 were associated with WHO grade III lesions 
[113] (Figure 5). In regard to tumor location, mRNA expression analysis distinguished between 
supratentorial WHO grade II and III tumors. In contrast, infratentorial ependymomas could not that 
easily be graded by their mRNA expression profiles, suggesting that in this location WHO grade III 
tumors differ by relatively few genetic changes from WHO grade II tumors [114].   
 
2.4.3. Myxopapillary ependymoma (WHO grade I) 
 
In spite of their benign clinical behavior, myxopapillary ependymomas are often aneuploid or 
tetraploid and carry numerous chromosomal imbalances, as determined by CGH analysis. In fact, the 
average number of chromosomal aberrations per tumor is considerably higher than that in 
ependymomas and anaplastic ependymomas [115]. The most common imbalances are concurrent gains 
of chromosomes 9 and 18 [116]. Additional recurrent alterations include gains of chromosomes 3, 4, 7, 
8, 11, 13, 17q, 20 and X, as well as losses of chromosomes 10 and 22. Also, cDNA profiles with high 
expression levels of HOXB5, PLA2G5 and ITH2 in myxopapillary ependymomas clearly differed 
from those in intracranial ependymomas [114], thus indicating that myxopapillary ependymomas are 
molecularly distinct from other ependymal tumors.  
 
2.4.4. Subependymoma (WHO grade I) 
 
Molecular genetic data on subependymomas are scarce. Cytogenetic investigation of two tumors 
revealed no structural or numerical abnormalities [117]. Individual cases studied for allelic losses on Int. J. Mol. Sci. 2009, 10  
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chromosome arms 10q and 22q, as well as for mutations in the hSNF5/INI1, NF2 and PTEN genes also 
did not show any aberrations [117]. 
 
3. Prognostic and predictive relevance of molecular changes  
 
A prognostic factor is any measurement available at the time of surgery that correlates with disease-
free or overall
 survival in the absence of systemic adjuvant therapy and thus conveys information on 
the natural course of the
 disease. In contrast, a predictive factor is any measurement
 associated with 
response to a given therapy. 
Many of the above described molecular alterations have been investigated in regard to their 
prognostic and/or predictive implications, but only few qualified as clinically relevant biomarkers. In 
this regard, the undisputably most important molecular alterations are hypermethylation of the MGMT 
gene in glioblastomas (Breakout Box 1) and combined deletions of chromosome arms 1p and 19q in 
oligodendrogliomas (Breakout Box 2). MGMT hypermethylation has been clearly identified as a 
predictive marker for the response of glioblastomas to alkylating chemotherapy with nitrosourea [33], 
temozolomide [34], or a combination of both [35]. The question of whether combined 1p/19q loss in 
oligodendroglial tumors, in addition to its predictive value for response to radiotherapy and 
chemotherapy with PCV, can also be regarded as a prognostic biomarker is controversially discussed. 
In the initial publication by Cairncross and colleagues in 1998 as well as in several retrospective 
follow-up studies, combined 1p/19q loss correlated with prolonged survival in patients with high-grade 
oligodendroglial tumors [3, 4, 87, 88, 91-93]. However, as patients with anaplastic oligodendrogliomas 
receive either radiotherapy or chemotherapy, or a combination of both after surgery as a standard of 
care, the prognostic value of combined 1p/19q loss cannot be evaluated independently of the 
administration of adjuvant treatment in high-grade oligodendroglioma patients. Several studies on low-
grade WHO grade II oligodendroglioma patients who were initially treated with surgery alone reported 
an association of 1p/19q deletions with a trend towards longer survival [92-95, 118]. Nevertheless, 
contrary findings have also been reported, which could not corroborate combined 1p/19q loss as a 
sensitive prognostic biomarker in patients with oligodendroglial tumors who did not receive 
radiotherapy or chemotherapy [98].   
While the molecular mechanism by which the MGMT repair protein counteracts the therapeutic 
effects of alkylating chemotherapy and thereby leads to treatment failure is obvious, the mechanism 
underlying the association of the 1p/19q allelic status with therapy response and longer survival still 
remains enigmatic. As outlined above, the relevant genes on 1p and 19q are still unidentified and it is 
unclear whether alterations in one or more genes on these chromosome arms, or rather in completely 
different chromosomal locations, may account for the clinically less aggressive behavior of 1p/19q-
deleted tumors. The observation that MGMT promoter hypermethylation is common in 
oligodendrogliomas with losses on 1p and 19q may point to at least one possible mechanism 
contributing to the chemosensitivity of these tumors [85]. Furthermore, one may speculate that not 
primarily the presence of 1p/19q loss but rather the absence of other prognostically unfavorable 
genetic alterations in 1p/19q-deleted tumors, e.g. losses of chromosome arms 9p, 10 and 18q or gains 
of chromosomes 7, 8q, 19q and 20, are responsible for the distinct clinical behavior [79]. All these 
unresolved issues will be subject to future molecular and translational studies.   Int. J. Mol. Sci. 2009, 10  
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4. Molecular genetics and glioma classification 
 
To date, gliomas are classified based on histological criteria according to the WHO Classification 
of Tumors of the Central Nervous System in its newest 2007 edition [2]. While immunohistochemistry 
using antibodies against a number of distinct antigens may support the histological classification, only 
few of the above described genetic alterations are consistently enough associated with defined glioma 
subtypes to qualify as auxiliary molecular diagnostic markers.   
Analysis for losses on 1p and 19q as well as mutations of the TP53 gene might help in the 
differential diagnosis between oligodendroglial and astrocytic gliomas. While oligodendrogliomas 
exhibit deletions on 1p and 19q in about two-thirds of cases, mutations of the TP53 gene are a 
hallmark genetic alteration found in about 60% of diffusely infiltrating astrocytic gliomas. Thus, the 
demonstration of allelic losses on 1p and 19q argues in favor of an oligodendroglioma, whereas TP53 
mutation or the immunohistochemical detection of a nuclear accumulation of the p53 protein supports 
the diagnosis of a diffuse astrocytoma. However, the sensitivity of both molecular alterations as 
differential diagnostic markers is not very high, indicated by the fact that about one third of 
oligodendrogliomas retain 1p/19 and about 40% of diffuse astrocytomas lack TP53 mutations and 
nuclear p53 accumulation. Consequently, 1p/19q testing cannot serve as a decisive diagnostic criterion 
to identify oligodendrogliomas, or in other words, it is not recommended to “rule in” or “rule out” a 
diagnosis of oligodendroglioma [71]. In line with this statement, the definition of oligodendroglioma 
in the latest WHO classification recognizes the frequent presence of 1p/19q deletions in these tumors 
but does not require this genetic alteration as an obligatory feature for making the diagnosis   
of oligodendroglioma. 
Another diagnostic problem that may prospectively be moderated by help of molecular markers is 
the differential diagnosis between diffuse and pilocytic astrocytomas. In addition to frequent TP53 
mutations, a recent integrated genomic analysis identified the isocitrate dehydrogenase 1 (IDH1) gene 
as frequently mutated in diffusely infiltrating astrocytic gliomas. Interestingly, in an initial screen on 
22 glioblastoma patients, mutations in the active site of IDH1 occurred in a large fraction of young 
patients and were associated with an increased overall survival in secondary glioblastoma patients 
[10]. A follow-up study analyzed IDH1 codon 132 mutations in a large series of 685 brain tumors 
comprising all major glioma subtypes and reported IDH1 mutation frequencies of up to 70% in diffuse 
astrocytomas, while virtually no mutations were detected in pilocytic astrocytomas [9]. In contrast, 
pilocytic astrocytomas -as recently indicated- are molecularly characterized by gene duplication/fusion 
or mutation of the BRAF gene on 7q34. These BRAF gene alterations occur in about 60-80% of 
pilocytic astrocytomas but are infrequent in diffusely infiltrating low-grade astrocytomas [46, 51]. Of 
note, this finding may not only bear diagnostic but also potential clinical relevance in regard to the 
development of novel targeted therapies. Tumors with duplications or activating mutations of the 
BRAF proto-oncogene showed significantly increased mRNA levels of BRAF and its downstream 
target, CCND1, as compared to tumors without these molecular alterations. In subsequent functional 
analyses both the stable silencing of BRAF through shRNA lentiviral transduction and 
pharmacological inhibition of MEK1/2, the immediate downstream phosphorylation target of BRAF, 
blocked the proliferation and arrested the growth of cultured tumor cells derived from low-grade Int. J. Mol. Sci. 2009, 10  
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gliomas [46]. Thus, pharmacological inhibition of the MAPK pathway may serve as a potential 
treatment option in pediatric low-grade astrocytoma patients. 
 
5. Comprehensive molecular analysis of gliomas by means of high-throughput profiling 
techniques  
 
The genome-wide search for new tumor suppressor genes and oncogenes as well as more 
sophisticated tumor-specific genomic or transcriptional signatures has been enormously facilitated by 
the development of novel array-based profiling techniques that nowadays are available for studies at 
the transcriptional as well as the genomic and epigenetic level. Recent studies indicate that array-based 
profiling techniques may serve as a valuable adjunct to mere histological classification and may 
facilitate diagnosis especially in tumors that exhibit borderline histopathological features.   
Genomic profiling by means of array-CGH closely paralleled histological classification and proved 
a powerful technique allowing for an automated genomic profiling of gliomas [119]. Microarray-based 
gene expression profiling was capable of classifying diagnostically challenging malignant gliomas in a 
manner that better correlated with clinical outcome than did standard pathology [120]. Moreover, gene 
expression profiling turned out to be an even more powerful survival predictor than histological grade 
or patient age [121]. While the standard implementation of whole-genome expression chips in routine 
diagnostics is not realistic due to its lack of cost-effectiveness, microarray-derived diagnostic and 
prognostic signatures comprising a restricted number of highly distinctive transcripts reliably classified 
gliomas into histologically unrecognized biological and prognostic groups [121-123]. Thus, microarray 
analysis has the potential to unveil confined expression signatures that in a routine diagnostic setting 
can identify clinically relevant patient subsets.  
Recent milestones are the publications of two large-scale multi-dimensional studies, one by Johns 
Hopkins researchers in Science [10], the other by The Cancer Genome Atlas Research Network in 
Nature [124]. Parsons and colleagues investigated 22 human glioblastoma samples for genome-wide 
DNA copy number and gene expression aberrations as well as somatic mutations in 20,661 protein 
coding genes. In addition to the identification of yet unknown IDH1 mutations, integrative data 
analysis identified a set of glioblastoma candidiate cancer genes that mainly functioned within the 
TP53, RB1 and PI3K/PTEN signaling pathways [10] (Figure 6). 
Integrative analysis of DNA copy number, gene expression and DNA methylation profiling in 206 
human glioblastomas by The Cancer Genome Atlas Research Network came to fairly similar results. 
The important pathways, each of which was found to be disrupted in more than three-quarters of 
glioblastomas were the CDK/cyclin/CDK inhibitor/RB pathway, which is involved in the regulation of 
cell division; the p53 pathway, which is involved in response to DNA damage and cell death; and the 
RTK/RAS/PI3K pathway, which is involved in the regulation of growth factor signals (Figure 6). 
Large-scale sequencing in a subset of 91 human glioblastomas for mutations in 601 selected genes 
additionally revealed ERBB2 gene mutations in 8% of glioblastomas, NF1 gene mutations in 14% and 
PIK3R1 mutations in closely 10% of glioblastomas, i.e. at slightly higher incidences as noted   
before [124-126]. 
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Figure 6. Core pathways involved in the pathogenesis of gliomas. 
 
Note the interrelationships between p53, RB, growth factor receptor, PTEN/PI3K/AKT and RAS 
signaling on the regulation of cell proliferation and apoptosis. While TP53 mutation, amplification 
of  MDM2/MDM4 or p14
ARF deletion/methylation inhibits apoptosis, alterations in p16
INK4a, 
p15
INK4b, p18
INK4c and p21
waf1 disinhibit cell cycle progression at the G1/S-phase checkpoint via 
cyclin-dependent kinases by phosphorylation of RB1 and release of E2F transcription factors. 
Amplification, overexpression or mutation of growth factor receptors stimulates cell proliferation 
and inhibits apoptosis through both the RAS as well as the PI3K/AKT signaling pathway. The RAS 
signaling pathway can be alternatively activated by mutations in the NF1, the PI3K/AKT signaling 
pathway by mutations in the PTEN gene and less commonly, the PIK3CA or the PIK3R1 gene. 
 
These molecular alterations may impact future treatment strategies. For example, as PIK3R1 
encodes the regulatory protein p85a subunit, response to PI3K inhibitors may depend on whether the 
tumors bear mutations in this specific gene or not. Also, in regard to predicting sensitivity and the 
development of resistence to temozolomide the Cancer Genome Atlas Research Network added further 
support for a role of the DNA mismatch repair system. MGMT methylation in conjunction with 
temozolomide treatment may lead to a loss of mismatch repair function by introduction of mutations in 
mismatch repair genes [127, 128]. Thus, patients who initially responded to frontline therapy may 
evolve treatment resistence by developing a hypermutator phenotype. As a consequence, selective 
strategies targeting mismatch-repair-deficient cells would represent a rational upfront combination Int. J. Mol. Sci. 2009, 10  
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with alkylating agents to prevent or minimize resistence to temozolomide [127]. A further recent study 
aiming at the identification of molecular profiles specific for treatment resistance to temozolomide 
identified a “glioma stem cell" or "self-renewal" expression signature as a predictor of poor survival 
[129]. Dominated by HOX genes and containing the putative glioma stem cell marker Prominin-1 
(CD133), this signature proved an independent prognostic factor also in multivariate analysis, adjusted 
for  MGMT methylation status. Thus, high-throughput profiling approaches might help to uncover 
mechanisms of treatment resistence and could accelerate the generation of therapeutically   
relevant biomarkers. 
 
6. Conclusions 
 
In this review we have summarized the most important cytogenetic and molecular changes 
associated with the different histological subtypes and grades of gliomas. Though molecular glioma 
classification is still in its infancy, tremendous advances have been made in regard to the exploitation 
of molecular changes for complementary diagnostic purposes and the establishment of novel predictive 
and prognostic biomarkers. High-throughput profiling techniques in conjunction with sophisticated 
bioinformatic integrative tools are emerging to revolutionize our knowledge about the complexity of 
the disease. The identification of glioma core pathways will enable us to deal with this complexity, 
especially in regard to the development of novel efficient targeted therapies. 
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